PROS1 and infection: Neutralizing monoclonal antibodies include sotrovimab (GSK4182136 or S309), bebtelovimab (LY-CoV1404), bamlanivimab-etesevimab (LY-CoV016-LY-CoV555), and casirivimab-imdevimab (REGN-CoV2), which prevent infection of human cells by blocking the S-protein–ACE2 attachment and mediate SARS-CoV-2 entry into the human respiratory epithelial cells (Tiecco G et al., 2022).